Drug intelligence / Profile preview

MWX205

Development stage: Phase 1
Lead developer: Shanghai Minwei Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

MWX205 is a monoclonal antibody designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), currently under development by Shanghai Minwei Biotechnology for the treatment of dyslipidemia. By binding to PCSK9, MWX205 prevents the degradation of low-density lipoprotein receptors (LDLR) on the surface of liver cells, thereby enhancing the clearance of LDL cholesterol from the plasma. The drug is being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and lipid-lowering efficacy, with a focus on providing a long-acting therapeutic option for patients with hypercholesterolemia.

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on MWX205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MWX205.

Explore the full profile